Erythropoietin (EPO) and LGD-4033 Interaction

Monitor
Mechanism-based 51% confidence

Erythropoietin (EPO) and LGD-4033 have an interaction requiring monitoring for interaction with 51% confidence. Both Erythropoietin (EPO) and LGD-4033 can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar). These compounds primarily affect different organ systems.

Compound Profiles

Erythropoietin (EPO)

EPO | Red Blood Cell Stimulating Hormone

EPO binds to erythropoietin receptors (EPOR) on erythroid progenitor cells in bone marrow, activating three interconnected signaling pathways: JAK2/STAT5, PI3K/AKT, and RAS/MAPK. This promotes survival of red blood cell precursors by protecting them from apoptosis, accelerates proliferation and differentiation of erythroid cells, and increases hemoglobin production.

Half-life: 4-12 hours (IV), ~25 hours (SubQ) Typical dose: 50-300 IU/kg based on medical indication metabolic
epo receptor blood pressure raisingcarcinogenic risk
View full profile

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Half-life: ~24-36 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskestrogenic
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
Pancreas
low

Shared Safety Flags

2x 2 compounds raise blood pressure (Erythropoietin (EPO), LGD-4033). Monitor BP daily and consider cardiovascular support.
2x 2 compounds share the carcinogenic-risk safety flag (Erythropoietin (EPO), LGD-4033). Monitor accordingly.

Frequently Asked Questions

Can I take Erythropoietin (EPO) with LGD-4033?

Yes, but with caution. Both Erythropoietin (EPO) and LGD-4033 can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar). Regular monitoring is advised.

Is Erythropoietin (EPO) and LGD-4033 safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: blood pressure raising, carcinogenic risk. Monitor accordingly.

What are the interactions between Erythropoietin (EPO) and LGD-4033?

Both Erythropoietin (EPO) and LGD-4033 can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar). This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.

How should I time Erythropoietin (EPO) and LGD-4033?

Erythropoietin (EPO) has a half-life of 4-12 hours (IV), ~25 hours (SubQ) and LGD-4033 has a half-life of ~24-36 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Erythropoietin (EPO) vs LGD-4033

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.